#United States #New York #Securities Fraud #Pomerantz Law Firm #PETMED EXPRESS

Pomerantz Law Firm Investigates PetMed Express, Inc.

The Pomerantz Law Firm has initiated an investigation aimed at protecting the interests of investors in PetMed Express, Inc., a company listed on NASDAQ under the ticker symbol PETS. This investigation arises amidst serious allegations of potential securities fraud and other unlawful business practices involving the company’s management, including certain officers and directors. Investors who believe they may have been affected by these developments are encouraged to contact the firm for more information.

Background of the Investigation

The concern has intensified following a series of troubling announcements from PetMed that have significantly impacted its stock price. On June 10, 2025, PetMed released a statement indicating a delay in the announcement of its fourth-quarter and annual earnings for the fiscal year 2025. The company cited the need for more time to finalize year-end audits as the reason. This news resulted in a considerable drop in PetMed’s stock price, which fell by $0.47, equating to a 11.22% decline, closing at $3.72 per share by June 11, 2025.

Subsequently, on July 1, 2025, PetMed issued another announcement stating that the filing of its Annual Report for the 2025 fiscal year would be delayed as the firm was undergoing an internal investigation focused on revenue recognition practices. This announcement further rattled investor confidence, leading to another decrease in stock value, this time by $0.05, or 1.51%, lowering the share price to $3.27.

The situation further deteriorated when, on November 12, 2025, PetMed disclosed its inability to file its quarterly report for the third fiscal quarter in a timely manner without unreasonable effort. This was attributed to the need for additional time to conclude the earlier revealed investigation by the company’s Audit Committee, which led to a drastic fall in the stock price of $0.94, marking a staggering 32.41% drop and closing at $1.96 per share on November 13, 2025.

The Role of Pomerantz LLP

Pomerantz LLP, established over eighty years ago, is recognized as one of the leading firms in corporate, securities, and antitrust class action litigation. They are known for their relentless pursuit of justice on behalf of investors who may be victims of securities fraud or corporate misconduct. The firm was founded by Abraham L. Pomerantz, a pioneering figure in the field of securities class action litigation, contributing significantly to protecting investor rights.

Pomerantz has successfully secured multimillion-dollar settlements for class members in numerous cases demonstrating commitment to holding corporations accountable for unethical practices. Given their background, the firm is uniquely positioned to investigate these recent claims surrounding PetMed, ensuring that any potential victims of corporate wrongdoing are adequately represented.

How Investors Can Get Involved

Investors who believe they might have been affected by these developments involving PetMed Express, Inc. are strongly encouraged to reach out to Danielle Peyton at Pomerantz Law Firm. She can be contacted via email at [email protected] or by phone at 646-581-9980, extension 7980. The firm is actively seeking to compile information on the experiences of affected shareholders to move forward with legal actions, including a potential class action lawsuit.

Conclusion

The ongoing investigation highlights the vital role of law firms like Pomerantz in safeguarding investor interests in the face of corporate mismanagement and malfeasance. As developments unfold, both current and potential investors in PetMed should stay informed about their rights and the steps they can take if they have incurred losses due to the company’s reported actions.